Anamorelin HCl
Phase 3Small molecule
Anamorelin HCl is one of 54 small molecule programs targeting Cachexia. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Anamorelin HCl
HHelsinn Therapeutics (U.S.), Inc
Phase 3
PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Treatment
GSKPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anamorelin HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHelsinn Therapeutics (U.S.), Inc